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Introduction
Aneurysmal subarachnoid haemorrhage (SAH) is a dev-
astating disease first described in the era of Hippocrates.
Despite advances in treatment, 1-month case fatality
remains as high as 35 %, with around one-third of sur-
vivors needing lifelong care and a further third having
residual cognitive impairment that affects functional
status and quality of life. The immediate and delayed
effects of SAH on outcome have recently been reviewed
in Intensive Care Medicine [1]. There have been advances
in the treatment of this devastating condition aimed at
reducing early (mainly re-bleeding) or late complications,
particularly delayed cerebral ischemia (DCI). The
importance of treatment in high-volume centres by a
multidisciplinary team cannot be over-emphasised [2].
Endovascular coiling of intracranial aneurysms rep-
resents a major advance in the treatment of SAH and
allows minimally invasive and effective treatment. Flow-
diverting stents, with or without coils, are an increasingly
employed strategy that allows even complex aneurysm to
be treated minimally invasively [3]. Clipping of the
aneurysm remains an option in the minority of cases that
cannot be secured via the endovascular route. Early
aneurysm control reduces the risk of re-bleeding and
allows maintenance of higher systemic blood pressure to
prevent or treat cerebral hypoperfusion. Once the aneu-
rysm is secured, the intensive care management of SAH
involves optimization of systemic physiology, and pre-
vention or treatment of DCI and non-neurological
complications. Consensus guidelines on the critical care
management of SAH have recently been published [2].
Delayed cerebral ischemia
DCI is a term applied to any neurological deterioration,
including focal neurological deficits and altered con-
sciousness, which persists for more than 1 h and cannot
be explained by physiological, radiological or laboratory
abnormalities. It peaks 4–10 days after the ictus, persists
for several days and is second only to the initial hemor-
rhage in terms of morbidity and mortality. Although DCI
has been attributed to cerebral vasospasm, the exact
relationship between the two is unclear. DCI can occur in
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the absence of vasospasm and vice versa, and brain
ischemia often involves more than one vascular territory.
Other mechanisms contributing to DCI include distal
vascular dysautoregulation, micro-thrombi, direct neuro-
toxic effects, inflammation and cortical spreading
depolarizations (SDs) [4]. SDs are pathological events
characterized by near-complete sustained depolarization
of neurons and astrocytes that result in secondary injury
related to mitochondrial damage, accumulation of intra-
cellular calcium and excitotoxicity. SDs, which can only
be detected by electrocorticography, have been reported
in up to 70 % of SAH patients. They are associated with
DCI and worse outcome, and management should focus
on controlling variables such as pyrexia, hypoxia, hypo-
glycemia and systemic hypotension which increase the
incidence and duration of SDs [5].
A combination of hypervolemia, hemodilution and
hypertension (triple H therapy) has historically been the
mainstay of treatment to prevent and treat DCI, but the
focus of cardiovascular management after SAH is now on
a single H—hypertension [2]. Prophylactic hypervolemia
is not effective in increasing CBF or improving neuro-
logical outcome, and there is some evidence of harm from
overly aggressive filling [6]. Euvolemia is the target for
both prophylaxis and treatment of DCI, and hemodilution
has no place [2]. Induced hypertension can be effective in
reversing DCI, and systemic blood pressure should be
increased in a stepwise fashion guided by assessment of
neurological function, neuromonitoring or radiological
evidence of improved perfusion. The higher blood pres-
sure should be maintained for 2–3 days and gradually
weaned while monitoring for deterioration in clinical and
neuromonitoring variables [2]. There is preliminary evi-
dence that early goal-directed hemodynamic therapy
might reduce the risk of DCI and improve outcome after
SAH [7], but large, randomized controlled outcome
studies are required before widespread adoption into
clinical practice.
Several pharmacological agents which target the
diverse pathophysiology of DCI have been investigated,
but only nimodipine has been proven to improve outcome
[1]. Despite the multiple beneficial effects of statins on
vascular function, a recent multicentre randomized phase
3 trial found no benefit of simvastatin on short- or long-
term outcome after SAH [8]. In a recent meta-analysis,
intravenous magnesium administration was associated
with a reduced incidence of DCI but not with beneficial
effects on mortality or functional outcome [9]. Endothe-
lin-A antagonists have been studied extensively after
SAH because of the key role that endothelin plays in
maintaining vascular tone. In randomized controlled tri-
als, the endothelin-A antagonist clazosentan reduced
angiographic vasospasm but had no significant effect on
outcome [10]. Attention has also focussed on agents
affecting the coagulation cascade because of the potential
role of microthrombosis in the pathogenesis of DCI. A
meta-analysis of seven randomized controlled trials of
anti-platelet agents identified a trend towards improved
outcome but also a higher risk of intracranial haemor-
rhagic complications [11].
Neuromonitoring
In addition to clinical neurological examination in con-
scious patients, serial transcranial Doppler (TCD)
ultrasonography supplemented by vascular and perfusion-
imaging studies is the mainstay of monitoring for DCI.
While such snapshots in time provide valuable informa-
tion, multimodal brain monitoring allows real-time
bedside assessment of the efficacy of hemodynamic
augmentation to prevent or treat DCI. This is particularly
important when clinical neurological examination is
limited in sedated or poor-grade patients.
Increased ICP is common after SAH, particularly early
after the ictus and in comatose patients [12]. The indi-
cations for ICP monitoring are often inter-related with the
need to treat obstructive hydrocephalus, so a ventricular
catheter is the optimal ICP monitor, being both a diag-
nostic and therapeutic modality. Intracranial hypertension
and lack of ICP response to medical therapy appear to be
associated with DCI and poor clinical outcome after SAH,
and ICP and CPP monitoring have a role in guiding
therapy. Multimodal cerebral monitoring, including brain
tissue oxygen tension, TCD, cerebral microdialysis and
electrophysiological monitoring in addition to ICP, allows
individualized therapy with the aim of preventing or
minimizing secondary ischemic injury [13]. Monitoring
allows early detection of DCI and identifies end points for
cardiovascular augmentation in its management. Changes
in brain tissue oxygenation and biochemistry may identify
impending or actual cerebral hypoxia/ischemia before
changes in other monitoring modalities or clinical status,
but it remains to be determined whether interventions
directed towards normalization of these variables affects
outcome. Data from small studies investigating the effi-
cacy of multimodal neuromonitoring-guided treatment
after SAH have been encouraging, but outcome data are
lacking [12]. Figure 1 shows a practical approach to
monitoring-guided management of DCI after SAH.
Seizures
Using surface electroencephalography (EEG), seizures
are recorded in around 8 % of patients after SAH but
invasive EEG monitoring identifies seizure activity in
almost 40 %. Continuous EEG monitoring is the only
reliable way to detect subclinical seizures, and it may also
predict DCI many hours in advance of clinical symptoms
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[14]. Actual seizures must be treated aggressively but
universal prophylaxis remains controversial. Three days
of treatment offers similar seizure prevention and better
outcome than longer-term therapy [2]. Phenytoin has been
associated with cognitive effects and poor outcome and,
although of equal efficacy in controlling seizures, leveti-
racetam is often chosen for the management of early-
onset seizures because of its more favourable side-effect
profile [15].
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